Genitourinary Cancers Symposium (ASCO GU) | Conference

Antibiotic Use May Damper the Efficacy of Checkpoint Inhibitors

February 14th 2017

Use of antibiotics up to a month before treatment with a checkpoint inhibitor may decrease the efficacy of the immunotherapy agent, results of a retrospective analysis show.

Durable Responders Emerge Even After Stopping Their PD-1/PD-L1 Therapy for Kidney Cancer

February 14th 2017

Some patients who had to stop their PD-1/PD-L1 immunotherapy because of an immune-related adverse event proved to be sustained responders, even after being off the therapy for more than 6 months.

Dr. Srinivasan on Targeted Therapies for Non-Clear Cell RCC

February 23rd 2016

Ramaprasad Srinivasan, MD, PhD, staff clinician, Urologic Oncology Branch, National Cancer Institute, discusses the need for targeted therapies for patients with non-clear cell renal cell carcinoma (RCC) and the types of agents these patients are likely benefit to from.

Dr. Emberton on Focal Therapy Techniques in Prostate Cancer

February 23rd 2016

Mark Emberton, MD, professor of Interventional Oncology, Division of Surgery and Interventional Science, University College London Hospitals, clinical director, Clinical Effectiveness Unit, Royal College of Surgeons of England, discusses techniques of focal therapy in patients with prostate cancer.

Cory Abate-Shen on Bladder Cancer Modeling

January 11th 2016

Cory Abate-Shen, PhD, research faculty, Columbia Urology, Columbia University Medical Center, discusses the challenges of bladder cancer modeling.

Oral HDAC Inhibitor Improves Antitumor Activity of IL-2 in mRCC

January 11th 2016

A selective class I oral histone deactylase inhibitor may increase the antitumor effect of high- dose interleukin-2 in renal cell carcinoma.

Nivolumab's Survival Benefit Sustained Across RCC Subgroups

January 11th 2016

Nivolumab’s second-line survival benefit in renal cell carcinoma was consistent across subgroups categorized by patient risk status, prior treatment, and degree of metastases, according to an update of the phase III CheckMate-025 trial.

Dr. Hamstra on Length of Radiation Treatments for Patients With Prostate Cancer

January 11th 2016

Daniel A. Hamstra, MD, PhD, assistant professor of Radiation Oncology, University of Michigan Health System, discusses clinical trials comparing the length of radiation treatments for patients with prostate cancer.

Hypofractionated Radiotherapy May Be New Standard of Care in Prostate Cancer

January 9th 2016

Hypofractionated radiotherapy demonstrated similar toxicity and was noninferior to standard radiation therapy for preventing PSA increases or disease recurrences for men with intermediate-risk prostate cancer.

Atezolizumab Update Affirms Activity in Bladder Cancer

January 9th 2016

Second-line treatment with atezolizumab (MPDL3280A) led to durable responses in patients with locally advanced or metastatic urothelial carcinoma.

Combo of Celecoxib and Zoledronic Acid Improves Survival in Metastatic Prostate Cancer

January 9th 2016

Adding celecoxib and zoledronic acid to standard treatment extended survival in men with metastatic prostate cancer commencing first-line hormone therapy, according to updated data from the STAMPEDE trial.

First Checkpoint/Chemo Combo Study for Urothelial Cancer Falls Short

January 9th 2016

The addition of the CTLA-4 inhibitor ipilimumab to cisplatin and gemcitabine did not significantly improve overall survival for patients with metastatic urothelial cancer.

Avelumab Spurs Responses in Refractory Metastatic Urothelial Cancer

January 9th 2016

The investigational anti-PD-L1 antibody avelumab demonstrated antitumor activity with an acceptable safety profile in a phase Ib trial of patients with metastatic urothelial cancer refractory to standard therapy.

Dr. Elizabeth Plimack on Immunotherapy Potential in Bladder Cancer

January 9th 2016

Elizabeth Plimack, MD, MS, Associate Professor, Director of Genitourinary Clinical Research at Fox Chase Cancer Center, discusses immunotherapy in bladder cancer.

Dr. Kibel on Take-Home Messages in Field of Genitourinary Cancers

January 9th 2016

Adam S. Kibel, MD, disease center leader, urology chief, urologic surgery, Brigham and Women's Hospital, professor of Surgery, Harvard Medical School, Dana-Farber Cancer Institute, discusses take-home messages for community oncologists out of the 2016 Genitourinary Cancers Symposium.

Dr. Choueiri on Significance of CheckMate-025 Study for RCC

January 8th 2016

Toni K. Choueiri, MD, clinical director, Lank Center for Genitourinary Oncology, director, Kidney Cancer Center, senior physician, Dana-Farber Cancer Institute, associate professor of Medicine, Harvard Medical School, discusses the significance of the CheckMate-025 for renal cell carcinoma.

Docetaxel First Choice After Abiraterone in 50% of Patients with mCRPC

January 8th 2016

A post hoc analysis of the COU-AA-302 clinical trial suggests that docetaxel has antitumor activity as first subsequent therapy following disease progression with abiraterone acetate in men with chemotherapy-naïve, metastatic castration-resistant prostate cancer.

Dr. Siefker-Radtke on Advancements in Small Cell Urothelial Cancer

January 8th 2016

Arlene O. Siefker-Radtke, MD, associate professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, clinical co-leader, Bladder SPORE Executive Committee, discusses treatment advancements in small cell urothelial cancer.

Can Aspirin Avert Lethal Prostate Cancer? Long-term Study Suggests a Possible Role

January 4th 2016

Aspirin’s benefits may now extend to reducing the risk of deadly prostate cancer, according to the results of an observational study which found that previously undiagnosed men who took regular aspirin had a 24% lower risk of developing a lethal form of the disease.

Liquid Biopsy Paves Way for Personalized Selection Tool in Prostate Cancer

January 4th 2016

The non-invasive liquid biopsy, if validated, could lead to the development of a personalized selection tool in men with advanced prostate cancer.

NEXT PAGE
PREVIOUS PAGE